Is RYAN a Buy? What to Consider in 2026

Last updated July 2026

Short answer

The bull case for Ryan Specialty Holdings (RYAN) rests on E&S market tailwind: Ryan Specialty is a leading intermediary in the excess and surplus lines market, which has grown for years as more complex, catastrophe-exposed, and hard-to-place risks flow out of the standard admitted market. Revenue (TTM) is ~$3.0B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The biggest near-term risk is insurance-pricing cyclicality: management has pointed to pronounced property-rate declines and intensifying competition, guiding to mid-single-digit organic growth and a modest margin decline for the year, with one quarter guided near zero organic growth. Whether RYAN is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.

Ryan Specialty Holdings is an international specialty insurance intermediary founded by Patrick Ryan (who also founded Aon). It sits between retail insurance brokers and carriers, operating two core engines: wholesale brokerage (led by RT Specialty, one of the largest E&S and binding-authority platforms in the US) and underwriting management, where its managing general underwriters (MGUs) hold delegated authority from carriers to underwrite niche risks in areas like energy, healthcare, construction, and enterprise risk. It does not take underwriting risk on its own balance sheet; it earns commissions and fees for placing and structuring hard-to-place specialty coverage. The investment picture is one of a fast-growing, acquisitive distributor riding the multi-year shift of business into the excess and surplus lines market. Revenue reached roughly $795 million in Q1 2026 (up about 15% year over year, with organic growth near 12%), and the company has partnered with 55-plus firms through acquisition since inception. The tension is valuation and cyclicality: RYAN trades at a rich trailing multiple, and management has flagged that pronounced property-rate declines and intensifying competition are pressuring organic growth and margins into 2026.

What's the case for buying RYAN?

1. E&S market tailwind

Ryan Specialty is a leading intermediary in the excess and surplus lines market, which has grown for years as more complex, catastrophe-exposed, and hard-to-place risks flow out of the standard admitted market. As long as this structural migration continues, it feeds Ryan's wholesale placement and binding-authority volumes.

2. Delegated underwriting (MGU) mix

The Underwriting Management specialty, where MGUs hold delegated authority from carriers, generated a meaningful share of net commissions and fees and carries attractive economics. Expanding this higher-margin, stickier business is a core part of the growth story and helps diversify away from pure brokerage.

3. Acquisition-led expansion

Ryan has built scale through 55-plus acquisitions of specialty firms and MGUs across geographies, and continues to acquire teams and books to add niches and international reach. Deployed capital and integration of these deals contribute a few points of growth on top of organic gains.

4. Organic growth engine

The firm has posted double-digit organic growth for several years, driven by new business wins, share gains from retail brokers, and specialty expertise. Sustaining organic growth as insurance pricing normalizes is the swing factor for the multiple.

What are the risks to RYAN?

The biggest near-term risk is insurance-pricing cyclicality: management has pointed to pronounced property-rate declines and intensifying competition, guiding to mid-single-digit organic growth and a modest margin decline for the year, with one quarter guided near zero organic growth. Softer rates directly reduce commission-based revenue. The stock also trades at a high trailing multiple, so any growth disappointment can compress the valuation sharply. Acquisition-heavy growth brings integration, goodwill, and leverage risk, and the company carries a meaningful debt load. Finally, it depends on relationships with carriers for delegated underwriting capacity, which can tighten in a downturn, and it operates in a competitive field against larger and well-capitalized wholesalers.

How is RYAN valued? (as of July 2026)

Price

$41.75

Market cap

$11.02B

P/E (TTM)

50.91

Forward P/E

17.75

Price / book

8.46

Beta

0.60

52-week range

$29.28 to $66.25

Snapshot for RYAN as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.

Revenue (TTM): ~$3.0B
Q1 2026 revenue: ~$795M (up ~15% YoY)
Organic growth (Q1 2026): ~11.8%
Adjusted EBITDA margin: ~29%
Market cap: ~$11B
P/E (TTM): ~54x (fwd ~19x)

Ryan Specialty grew Q1 2026 revenue about 15% to roughly $795 million and returned to a quarterly net profit, with adjusted EPS up about 20%. The trailing P/E near 54x looks steep and reflects growth expectations, while the forward multiple near 19x is far lower because analysts expect earnings to catch up. Management trimmed full-year organic growth guidance to mid-single digits and expects some margin decline as property rates soften.

How do you decide if RYAN is a buy?

Rather than asking whether RYAN is a buy in the abstract, it tends to help to answer four questions:

Thesis: do you believe the case above, and is it still true today?
Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
Overlap: check whether you already hold RYAN indirectly through an index or sector ETF before adding more.

For the full picture, see the RYAN stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about RYAN against your real portfolio and see your actual exposure before deciding.

The bottom line on RYAN

The bottom line: Ryan Specialty Holdings's story right now is E&S market tailwind, with revenue (ttm) at ~$3.0B. If you believe that narrative continues, the call is about sizing RYAN sensibly and checking overlap with what you own; if you doubt it (the risk: the biggest near-term risk is insurance-pricing cyclicality: management has pointed to pronounced property-rate declines and intensifying competition, guiding to mid-single-digit organic growth and a modest margin decline for the year, with one quarter guided near zero organic growth.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.

More on RYAN

RYAN stock guide (what the company does, ETFs that hold it, similar stocks, and the themes it fits)
RYAN stock forecast (the drivers and risks shaping the outlook)
Does RYAN pay a dividend?

Build a basket around RYAN with Walnut

Use Ryan Specialty Holdings as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.

Create a free Walnut account

FAQ

Is RYAN a good stock to buy right now?

The case for Ryan Specialty Holdings right now is E&S market tailwind, with revenue (ttm) at ~$3.0B. If you believe that thesis holds, RYAN is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the biggest near-term risk is insurance-pricing cyclicality: management has pointed to pronounced property-rate declines and intensifying competition, guiding to mid-single-digit organic growth and a modest margin decline for the year, with one quarter guided near zero organic growth. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.

What does Ryan Specialty Holdings do?

Ryan Specialty Holdings is an international specialty insurance intermediary founded by Patrick Ryan (who also founded Aon).

What are the main risks of RYAN?

What does Ryan Specialty do?

It is a specialty insurance intermediary that connects retail insurance brokers with carriers. It runs wholesale brokerage (placing hard-to-place risks, largely in the E&S market) and underwriting management, where its MGUs hold delegated authority to underwrite niche risks for carriers. It earns commissions and fees, not underwriting profit.

Does Ryan Specialty take on insurance risk?

No. Ryan is an intermediary and distributor, not a risk-bearing insurer. It places coverage and underwrites on behalf of carriers under delegated authority, earning commissions and fees. The underwriting risk sits with the carriers that provide the capacity.

What is the excess and surplus (E&S) market and why does it matter to RYAN?

E&S covers risks that the standard admitted insurance market will not write, such as complex, catastrophe-exposed, or emerging exposures. Ryan is a leading wholesale intermediary in E&S, so the multi-year growth of that market has been a key tailwind for its placement volumes.

How did Ryan Specialty perform in Q1 2026?

Revenue was roughly $795 million, up about 15% year over year, with organic growth near 12%. The company returned to a quarterly net profit, and adjusted EPS rose about 20%. Adjusted EBITDA margin was around 29%.

Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell RYAN; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.